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 Despite the ongoing developments made in modern medical research, cancer 
remains the second most common cause of death in the United States [1]. Many 
modern treatments, such as radiation therapy and chemotherapy, have numerous 
adverse side-effects that may not become evident until months or years after treatment 
has ended [2 & 3]. Additionally, there exist few effective treatments for individuals 
diagnosed with late-stage cancers. There is a great need for continued research and 
development of novel treatment options to facilitate better clinical outcomes of cancer 
patients.  
 Our research of the drug AS1411 aims to address this need for improved cancer 
therapeutics. AS1411 is a guanine-rich oligonucleotide optimized for its anti-proliferative 
activity of cancer cells. Guanine-rich oligonucleotides (GROs) are short chains of 
nucleotides ranging from 
approximately 13 to 25 
nucleotides and are 
predominately composed of 
guanine residues [4]. GROs 
exhibit a number of properties 
that amplify their activity, 
including spontaneously 
forming G-quadruplex 
structures (Figure 1) which 
increase the compound’s 
Figure 1. An example structure of a G-quadruplex in two 
views. (Left) Demonstrates guanine residues forming 
hydrogen bonds in the presence of a cation to create a 
stable quadruplex. (Right) Illustrates how the backbone of 
the oligonucleotide can loop into a stable conformation. 
Adapted from Ma et al. 2013 [7]. 
ability to resist degradation by nucleases [5]. While the exact quadruplex structure of 
AS1411is unknown, at least 8 different forms have been detected using a size exclusion 
chromatography [6]. Additionally, AS1411 has specificity for cancer cells because it is 
capable of binding to nucleolin, a protein that is highly expressed on the surface on 
many types of cancer cells [8].  
 AS1411 has shown promise in both in vitro and in vivo experiments. The GI50 
values (the concentration required for 50% growth inhibition) for AS1411 were 
remarkably low for almost every tested cancer cell line despite the fact of having little 
effect in normal cell lines at similar concentrations [5]. Notably, the compound also 
inhibited tumor growth in mouse models despite displaying no toxicity in normal tissues. 
These results imply that the anti-proliferative effects of AS1411 selectively target 
cancerous cells, unlike standard therapies. In 2003, AS1411 entered into a Phase 1 
clinical trial in patients with advanced cancers. During this trial, there were no reports of 
severe side-effects and varying degrees of clinical activity. Most patients experienced 
disease stabilization, but one patient experienced a complete response; within 11 
months [5]. Similar results were later replicated during phase 2 clinical trials, however 
the funding company, Antisoma, had to terminate ongoing trials due to the expensive 
failure of another drug compound in its pipeline [8]. AS1411 was tested in over 100 
patients but only demonstrated strong activity in 7. However, these 7 patients exhibited 
strong results including substantial shrinkage and the complete disappearance of 
tumors [9]. It was discerned that in order to apply and optimize AS1411, a better 
understanding of the mechanism of action was required [8 & 9]. 
 AS1411 is incorporated into the cell by macropinocytosis and that levels of 
macropinocytosis and anti-proliferative activity are correlated [10]. In particular, AS1411 
induces cell death through a novel pathway known as methuosis, in which the cells 
ingest numerous vesicles causing eventual cell lysis [10 & 11]. Methuosis is a novel 
nonapoptotic cell death pathway that is characterized by displacement of the cytoplasm 
by large fluid-filled vacuoles derived from macropinosomes that ultimately induce cell 
lysis. Notably, this pathway involves the hyperstimulation of a number of oncogenic 
pathways that ultimately result in cell death [12]. The involvement of these oncogenic 
pathways makes methuosis highly promising as a possible target for the treatment of 
aggressive or late-stage disease. Although numerous compounds and proteins have 
been implicated in the pathway, many aspects of the pathway remain unknown. 
 The accumulation of guanine ribonucleotides can lead to the arrest of the cell 
cycle and an inhibition of cellular growth in human cells [13]. Further studies have 
Figure 2. Reaction diagram representing the enzymatic activity of HGPRT. The enzyme serves 
as a transferase that converts guanine to guanosine monophosphate through the 
transference of a phosphoribosyl group from phosphoribosyl pyrophosphate to guanine. 
This creates guanosine monophosphate and pyrophosphate as end products.  
suggested that the degradation of GROs (including AS1411) to the monomers of 
guanine-based purine compounds (GBPCs) such as guanine, guanosine, and 
guanosine monophosphate dictate the anti-proliferative effects in vitro [14]. Additionally, 
these anti-proliferative effects are dependent on hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT), an enzyme in the purine salvage pathway (Figure 
2) [15]. HGPRT is a vital element of the purine salvage pathway and subsequently an 
important enzyme for creating the bases that will be sequestered into new DNA [16]. A 
loss of HGPRT function in cells makes them unable to recycle certain purines, and this 
causes deleterious effects. 
This can be seen in the 
severely shortened lifespans 
of patients affected by Lesch–
Nyhan syndrome, an inherited 
disorder caused by an HGPRT 
deficiency [17]. My current 
hypothesis (Figure 3) posits 
that AS1411 acts as a prodrug 
for guanine and that the anti-
proliferative activity should 
therefore be dependent upon 
the activity of HGPRT. Some 
studies in the Bates lab have 
indicated that metabolism to 
Figure 3. This image demonstrates a hypothesized life cycle 
of an AS1411 molecule after binding to a targeted cell. As 
indicated, the role of GBPCs and mechanisms of methuosis 
progression are not fully understood currently. 
guanine plays a role in AS1411 activity [unpublished]; however, more research is 
needed to elucidate the mechanism. This project will be combined with our previous 
unpublished research with the goal of definitively testing the stated hypothesis. 
Ultimately, this knowledge will serve to guide further studies for optimizing AS1411 as a 
potential cancer treatment. 
Specific Aims 
 The specific aim for this project was to investigate the possible role of HGPRT in 
the anti-proliferative activity of AS1411. If degradation to GBPCs is vital for AS1411 
activity, then the loss of HGPRT function should result in a decrease of the compounds 
exhibited anti-proliferative effects.  
Materials and Methods 
Materials 
 Oligodeoxynucleotides, AS1411 (5′-GGTGGTGGTGGTTGTGGTGGTGGTGG), 
and negative control oligonucleotide, CRO (5′-CCTCCTCCTCCTTCTCCTCCTCCTCC) 
were purchased in the desalted form from Integrated DNA Technologies (Coralville, IA). 
Guanosine and 6-thioguanine were purchased from Sigma (St. Louis, MO). Mouse 
monoclonal antibodies, α-tubulin (11H10, Cell Signaling, Danvers, MA) and HGPRT (F-
1, cat # SC-376938,Santa Cruz Biotech, Dallas, TX) were utilized along with anti-mouse 
(sc-2005, Santa Cruz Biotech) and anti-rabbit (sc-2004, Santa Cruz Biotech) antibodies 
linked to horseradish peroxidase.  Small interfering ribonucleic acids (siRNAs) targeting 
human HGPRT, s6887 (5’-GGAUAUGCCCUUGACUAUAtt-3’), s6888 (5’-
AAAUAGUGAUAGAUCCAtt-3’), and Silencer Select Negative Control #1 were 
purchased from Life Technologies (Carlsbad, CA). 
Cell Lines 
A549 cell lines were purchased from the American Type Culture Collection 
(ATCC) and grown in Dulbecco's Modified Eagle's medium (DMEM) media (Life 
Technologies) supplemented with 1% penicillin/streptomycin (Life Technologies) and 
10% fetal bovine serum (Life Technologies) in humidified incubators at 37 °C with 5% 
CO2. Cells were plated and incubated overnight to allow for adherence prior to 
treatment. 
Cell Lysis and Protein Collection 
Flasks containing cells were placed on ice and media was removed. Flasks were 
then washed with ice-chilled phosphate-buffered saline (PBS, Life Technologies). Cells 
were lysed in RIPA buffer [150 mmol/L NaCl, 2 mmol/L EDTA, 50 mmol/L Tris–HCl, 
0.25% deoxycholic acid, 1% IGEPAL CA-630 (pH 7.5)] containing protease and 
phosphatase inhibitors (Calbiotech, Spring Valley, CA) and collected using a cell 
scraper (TPP, Trasadingen, Switzerland) and clarified by centrifugation at 14,000 × g for 
10 min at 4 °C. Diluted clarified total cell lysates were analyzed using a Pierce™ BCA 
Protein assay kit against a standardized protein concentration curve derived from 
known bovine serum albumin (BSA) standards (Fisher Scientific, Waltham, MA). 
Protein Analysis by Western Blot 
 Samples for SDS-PAGE were prepared using 25 μg of protein, 4× loading buffer 
containing 10% β-mercaptoethanol, and distilled water to ensure samples of equal 
volumes. Samples were resolved using Novex 4 – 20% tris-gylcine gels (Life 
Technologies) and then transferred onto polyvinylidine fluoride membranes (Fisher 
Scientific) in Tris–glycine transfer buffer (Life Technologies) containing 20% methanol. 
Membranes were either blocked with 5% milk in tris-buffered saline containing 0.05% 
tween-20 (TBS-T) in TBS-T. The following primary concentrations were used for protein 
detection: HGPRT 1:500, and α-tubulin 1:1000. Secondary antibodies were used at a 
1:10,000 concentration. Membranes probed with HGPRT primaries were detected using 
SuperSignal® West Dura ECL (Fisher Scientific) while α-tubulin was detected using 
Pierce® ECL Western Blotting Substrate (Fisher Scientific). Chemiluminescence was 
visualized using Amersham Hyperfilm™ (GE Healthcare, Little Chalfont, United 
Kingdom). 
Cell Proliferation Assay 
A549 cells were plated at a density of 1000 cells per well in 96 well plates (TPP) 
and incubated overnight to allow for adherence. Cells were treated in triplicate wells 
with either oligonucleotide, GBPC, or siRNAs. After treatments of varying duration, MTT 
(Sigma) was added in the dark at 1/10th total sample volume, and cells were incubated 
for 4 hours. Lysis buffer (10% SDS in 0.01 N HCl) was added at half of the original 
sample volume and incubated overnight to ensure complete cell lysis and dissolution of 
crystals. Plates were read at 570 nm, and relative absorbance values were exported to 
Microsoft Excel® for further analysis [18 & 19]. GraphPad Prism was used to determine 
the level of statistical significance by ANOVA and/or t-test.  
HGPRT Knockdown via siRNA Transfection for Protein Analysis 
 A549 cells were transfected with Lipofectamine 2000 (Intivrogen, Carlsbad, CA) 
and Opti-MEM ® (Life Technologies) per manufacturer’s protocol. Briefly, cells were 
transferred to antibiotic free media for 1 hour before transfection. Cells were then either 
transfected with HGPRT siRNAs (s6887 & s6888), or negative control #1 siRNA (Life 
Technologies) as seen in Figure 4. After 4 hours, the media containing transfected 
reagents was replaced with complete media.  Transfected cells were evaluated for 
relative proliferation levels using MTT colorimetric assays or lysed for analysis of protein 
levels using western blots. 
 
 
Figure 4. Example plate demonstrating how treatment groups are further divided by 
transfection type. Each combination of treatment and transfection is represented by an 
average of three individual wells.  
Development of Thioguanine-Resistant A549 Cells 
A549 cells were grown to ~70% confluency and then transferred to new flasks 
containing a 1.5 µM 6-thioguanine (Sigma). After cells grew to confluency, they were 
passaged into new flasks with 3 µM increases in concentration of 6-thioguanine. This 
was repeated until final concentrations of 6 µM and 15 µM of 6-thioguanine were 
established.  
Results 
Determining Optimal Conditions for AS1411 Anti-Proliferative Effects  






in A549 lines, A549 
cells were plated at 
a density of 1000 
cells per well in 96 
well plates and 
incubated in 
complete media overnight to allow for adherence. Cells were then treated in triplicate 
wells with increasing concentrations of AS1411 and incubated for 72 hours before cell 
Figure 5. Relative proliferation levels of A549 cells treated with 
increasing concentrations of AS1411. Results from MTT 
colorimetric assay were normalized against a vehicle control. Error 
bars represent one standard deviation from the mean. 
proliferation assay were performed. Results were normalized to a vehicle control. 
Substantial decreases in relative proliferation were observed with a GI50 value of 
approximately 1.5 µM AS1411 (Figure 5). 
Determining Optimal Conditions for HGPRT Knockdown using siRNAs 
A549 cell lines were treated with HGPRT siRNAs to knockdown protein 
expression, and subsequent protein samples were analyzed by western blot to confirm 
knockdown. Initially, A549 cells were transfected with HGPRT siRNAs (s6887 & s6888), 





Figure 6. (A) Comparisons of HGPRT knockdown using s6887 (#1) & s6888 (#2) siRNA. 
Neither sample exhibits any detectable protein expression. Negative control siRNAs and 
non-transfected groups demonstrate comparable expression. Loading controls of α-Tubulin 
were even in expression across treatment groups. (B) Comparisons of HGPRT knockdown 
over 120 hours at 24 hour intervals. HGPRT levels decrease from 24 to 72 hours after 
transfection with siRNA s6887 and remains stable through the 120 hour time point.  
HGPRT levels were determined by western blot. α-Tubulin was also examined to 
ensure equal levels of protein loading. Cells treated by HGPRT siRNAs were found to 
decrease HGPRT expression to an undetectable level in comparison to negative control 
siRNA or non-transfected samples (Figure 6). Additionally, no detectable difference was 
noticed between knockdowns of HGPRT using s6887 or s6888 siRNAs. Additional 
samples were transfected and then lysed at 24, 48, 72, 96, and 120 hours in order to 
determine the longevity of HGPRT knockdown. Substantial knockdown was found to 
occur at 24 hours and increased until 72 hours. From 72 hours to 120, hours protein 
levels remained unchanged. The loading control of α-tubulin did not exhibit substantial 
changes at any time point.  
Analyzing AS1411 Anti-Proliferative Activity in HGPRT Deficient Cells 
To determine if the anti-proliferative activity of AS1411 was dependent on 
HGPRT function, cells were transfected with HGPRT siRNAs, treated with drug, and 
then measured for levels of relative proliferation. A549 cells were transfected with 
HGPRT siRNA (s6887), a negative control siRNA, or left untransfected. After 48 hours, 
cells were treated with AS1411, CRO, or a water vehicle control for 72 hours before 
relative proliferation was measured. Results indicate that HGPRT knockdown caused 
no significant variance in AS1411 treatment when compared to controls (Figure 7). 
Furthermore, there was no significant variation between the vehicle control groups, 
implying that transfection was not inherently toxic to the cells. Additionally, treatment 
with 5 μM AS1411 was found to significantly decrease proliferation (p < 0.01) when 
compared to CRO groups.  
To further investigate if the anti-proliferative activity of AS1411 is dependent on HGPRT 
function, transfection parameters were altered to ensure HGPRT knockdown. In the first 
variation of the transfection protocol (Figure 8 A), siRNA concentrations were increased 
from 20 nM to 40 nM in an attempt to create a more complete knockdown and 
determine if results were reproducible. Results from this trial demonstrate a high degree 
of similarity to previous findings. No significant variation was found in either the AS1411 
or vehicle control, and AS1411 treated cells experienced a significant decrease in 
proliferation in comparison to CRO controls (p < 0.05). For the next experiment, the 
Figure 7. Bar graph 
showing relative 
proliferation of A549 
cells across various 
treatment and 
transfection types. dH2O 





difference was observed 
between siRNA 
transfections in either 
the vehicle or AS1411 
treatment groups. 
AS1411 treatment did 
show a significant 
decrease in relative 
proliferation in contrast 
to CRO groups. Results 
from MTT colorimetric 
assay were normalized 
against the vehicle 
control. ** indicates a p-
value of < 0.01. 
siRNA transfection time was reduced from 48 to 24 hours to ensure that the plate would 
be processed by MTT assay within 120 hours of transfection because previous findings 
did not study siRNA knockdown efficacy outside this range (Figure 6, B). Results 
(Figure 8, B) from this test had a high degree of similarity to the original findings (Figure 
7). AS1411 and vehicle control treatment groups demonstrated no significant variation 
Figure 8. Variations in transfection protocol to investigate optimal knockdowns of HGPRT. 
 
(A) Bar graph representing relative proliferation with increased siRNA concentrations. Data was 
normalized to the untransfected vehicle control. No significant difference was seen between 
transfection types in either vehicle (dH2O) or AS1411 treated cells. AS1411 treatment 
demonstrated a significant decrease in relative proliferation in contrast to CRO groups, albeit 
lower than previous findings (* indicates p < 0.05).  
 
(B) Relative proliferation with decreased overall siRNA transfection time. No significant difference 
was seen between transfection types in either vehicle or AS1411 treatment groups. AS1411 
treatment did show a significant decrease in relative proliferation in contrast to CRO groups, 






















































































































































































































































































































































between transfection groups, and AS1411 was shown to have a significant decrease in 
proliferation when compared to the corresponding CRO treated cells (p < 0.05).  
Determining Optimal Conditions for GBPC Anti-Proliferative Effects in A549 and 
MDA-MB-231 Cells 
 
 As mentioned previously, guanine-based purine compounds (GBPCs), such as 
guanosine, have been shown to exhibit anti-proliferative effects in vitro [14]. 
Furthermore, their toxicity appears to be dependent on HGPRT function [15]. To 
determine if AS1411 activity is similar to that seen in cells treated with GBPCs, A549 
and MDA-MB-231 cells were treated 25 to 400 µM guanosine (Guo) ranging from 25 to 
400 µM for 72 hours before cell proliferation assays were performed. A549 cells 
Figure 9. Comparing guanosine 
activity in A549 and MDA-MB-
231 cells.  
 
(A) Graph showing relative 
proliferation of A549 cells 
treated with increasing 
concentrations of guanosine. 
A549 cells show a light response 
to guanosine treatment. Error 
bars represent one standard 
deviation from the mean.  
(B) Graph showing relative 
proliferation of MDA-MB-231 
cells treated with increasing 
concentrations of guanosine. 
MDA-MB-231 cells show a 
lessened response to guanosine 
treatment in comparison to 
A549 counterparts. Error bars 
represent one standard 
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demonstrated a dose-dependent response to Guo treatments (Figure 9, A); however, 
the anti-proliferative activity was not as substantial as seen with AS1411 at equivalent 
concentrations (Figure 4). A549 cells treated with 400 µM Guo demonstrated a relative 
proliferation of 60% compared to the control, whereas MDA-MB-231 cells at an identical 
concentration only demonstrated a decrease to 80% when compared to the control 
(Figure 9).  
GBPC Anti-Proliferative Activity in HGPRT Deficient A549 and MDA-MB-231 Cells  
 After determining the responsiveness of A549 and MDA-MB-231 cell lines to 
guanosine, further experiments sought to determine if siRNA knockdown of HGPRT 
would decrease the anti-proliferative activity caused by guanosine. Previous literature 
has demonstrated that the loss of HGPRT resulted in the loss of anti-proliferative 
activity upon exposure to guanosine [15]. If siRNA knockdown of HGPRT decreases the 
activity of Guo, then it would suggest that the transfection can effectively reduce 
HGPRT activity. However, if transfection is unable to significantly affect anti-proliferative 
activity in Guo treatment, then it would suggest that the knockdown is not thorough 
enough to fully negate HGPRT enzymatic activity. A549 and MDA-MB-231 cells were 
transfected with siRNAs targeting HGPRT, a negative control siRNA, or left 
untransfected. After 48 hours, cells were treated with increasing concentrations of Guo, 
AS1411, or vehicle for 72 hours before relative proliferation was measured. Results in 
A549 cells indicate that cells treated with a vehicle control and transfected with HGPRT 
siRNA displayed a decrease in proliferation of 35% in comparison to those transfected 
with a negative control siRNA or left untransfected (Figure 10). A dose-dependent 
response to Guo treatment was seen across the A549 cells, with 400 µM treatments 
reducing relative proliferation by 40-50% depending on transfection type. AS1411 
treated groups, however, still exhibited greater drops in proliferation of 60-65%. No 
significant difference was seen between transfection types in cells treated with 50 µM, 
Figure 10. Bar graph representing relative levels of proliferation in transfected A549 cells 
treated with increasing concentrations of guanosine (Guo). Guanosine stock solutions were 
prepared in DMEM media and dissolved with minimal amounts of base. DMEM with an 
identical concentration of base was used as a vehicle control. Treatment with AS1411 caused 
greater decreases in relative proliferation when compared to Guo treatments, and no 
significant difference was seen between AS1411 transfection groups. A dose-dependent 
response was seen across the guanosine treatment groups from 50 μm to 400 μm. Vehicle 
control cells transfected with HGPRT siRNAs demonstrated decreases in relative proliferation 
in comparison to negative control siRNAs and non-transfected controls. ** indicates p < 0.01 
and * indicates p < 0.05.  
100 µM, or 400 µM Guo. Although there was a statistically significant difference seen in 
200 µM Guo groups (p = 0.048), replication would be needed to confirm the results.  
Results in MDA-MB-231cells did not indicate a strong response to Guo 
treatment; however, cells transfected with either HGPRT siRNAs or negative control 
Figure 11. Bar graph representing relative levels of proliferation in transfected MDA-MB-
231 cells treated with increasing concentrations of guanosine (Guo). Cells transfected with 
either negative control siRNAs or HGPRT siRNAs demonstrated decreased proliferative in 
comparison to non-transfected cells, suggesting possible toxic side-effects from the 
transfection itself. Additionally, AS1411 treatments displayed greater levels of anti-
proliferative activity in comparison to Guo treatments. Unlike in A549 cells, MDA-MB-231 
cells did not exhibit a dose-dependent response to Guo treatment. * indicates p < 0.05 










siRNAs demonstrated similar levels of relative proliferation (Figure 11). This suggests 
possible toxic side-effects from the lipofectamine. Non-transfected cells treated with 
Guo consistently demonstrated a decrease in relative proliferation of ~40%. These 
outcomes are consistent with the findings of the dose response curve in which A549 
cells demonstrated a greater sensitivity to Guo treatment than MDA-MB-231 cells 
(Figure 9). Again, cells transfected with HGPRT siRNAs and treated with the vehicle 
demonstrated significant decreases in proliferation when compared to non-transfected 
cells, suggesting a toxic side effect with the loss of HGPRT function.   
Evaluating GBPC and AS1411 Anti-Proliferative Activity in 6-Thioguanine 
Resistant Cells 
 A549 cells were incubated with concentrations of 6-thioguanine (TG) in order to 
select for HGPRT mutant cells. Inside the cell, TG acts as an analog to guanine and can 
be recycled by HGPRT and then incorporated into the DNA [20]. This incorporation 
typically results in strand breakage and eventual cellular death; however, the loss of 
HGPRT activity can remove the toxic effects of TG [21]. Based on a previous protocol 
[22], HGPRT mutants were selected by increasing treatments of 6-thioguanine and then 
treated with increasing concentrations of Guo and AS1411. A549 cells incubated in TG 
and wildtype cells were plated for 24 hours, treated with a vehicle control, Guo, or 
AS1411 for 72 hours, and then relative proliferation was measured. Although no 
significant difference in proliferation was seen in the vehicle controls, TG treated cells 
did show increased proliferation across three of the four Guo treatments (50 µM, 100 
µM, and 200 µM). Additionally, TG treated cells demonstrated greater levels of 




  * 
Figure 12. Bar graph representing relative levels of proliferation in A549 cells and A549 cells 
incubated in 15 µM 6-thioguanine (TG). Guanosine stock solutions were prepared in DMEM 
media and dissolved with minimal amounts of base. DMEM with an identical concentration 
of base was used as a vehicle control. Cells were treated with increasing concentrations of 
Guo, AS1411, and a vehicle control. A549 cells and TG cells treated with a vehicle control 
did not display a significant difference in proliferation. Alternatively, a significant difference 
in proliferation was found in 50 µM, 100 µM, 200 µM, and AS411 treatments. 400 µM 
treatments did not show a significant difference in proliferation (p = 0.050). * indicates p < 
0.05. ** indicates p < 0.01.  
  *   * 
  ** 
  N.S. 
  N.S. 
Discussion 
Initial experiments were conducted to establish a baseline concentration for 
AS1411 anti-proliferative activity in A549 cells and to ensure that HGPRT expression 
could be knocked down by transfection with siRNAs. Investigations into the efficacy of 
AS1411 treatments in A549 cells demonstrated a GI50 for AS1411 of 1.5 µM (Figure 4). 
These findings are congruent with previous findings that cited the GI50 range for AS1411 
in A549 cells being approximately 2 µM [23]. Immunoblots of transfected cells were 
found to decrease expression of HGPRT when treated with either HGPRT siRNA 
(s6887 & s6888). This knockdown effect was seen to begin at 24 hours and last through 
120 hours. No difference in protein knockdown was found between the HGPRT siRNAs 
s6887 & s6888, so only s6887 was used for transfections. Non-transfected cells were 
used as a baseline for HGPRT expression, and cells transfected with a negative control 
siRNA were used to gauge whether or not transfection with lipofectamine altered protein 
expression. Cells transfected with negative control siRNAs and non-transfected cells 
were found to have similar levels of protein expression implying that transfection with 
lipofectamine did not alter HGPRT expression. Expression of α-tubulin was measured to 
ensure that equal amounts of protein were loaded during the immunoblot process. The 
loading controls did not exhibit any irregularities in expression that would discredit 
previous findings. 
After the GI50 of AS1411 in A549 cells and reliable HGPRT knockdown were 
established, A549 cells were transfected and then treated with AS1411 to test if HGPRT 
activity was necessary for AS1411 anti-proliferative effects. CRO (cytosine rich 
oligonucleotide) treatments in equal concentrations to AS1411 counterparts were used 
to determine if oligonucleotide treatment decreased relative proliferation as seen in 
previous studies with AS1411 [24]. Additionally, water was used as a vehicle control. In 
line with previous findings, AS1411 displayed strong anti-proliferative effects compared 
to vehicle and CRO control treatments. Transfected vehicle control treatments did not 
exhibit decreased proliferation, suggesting that transfection was not toxic to cells. 
Additionally, CRO treatments did not differ significantly to vehicle control treatments 
implying that non-specific oligonucleotide treatment was not toxic to cells. Levels of 
proliferation did not vary between cells treated with AS1411 and transfected with 
HGPRT siRNAs, negative control siRNAs, or left untransfected.  
These results could imply multiple outcomes. Since the downregulation of 
HGPRT seemingly did not alter AS1411 anti-proliferative activity, it is possible that the 
enzyme is not a necessary element for AS1411 activity, possibly because degradation 
is not an essential step in the drug pathway. Alternatively, transfections with HGPRT 
siRNAs may have knocked down most, but not all of the HGPRT in a cell. In this 
scenario, it is possible that a small amount of residual HGPRT was able to preserve the 
activity of AS1411. 
Additional tests were performed in order to explore the latter possibility. A549 
cells were transfected and treated with doubled concentrations of siRNA for comparison 
with the previous findings to determine if initial concentrations had produced an 
incomplete knockdown. The findings were congruent with previous results. Cells treated 
with AS1411 and water did not show any significant change in relative proliferation 
across transfection type, and AS1411-treated cells demonstrated lower relative 
proliferation when compared to either water or CRO groups (Figure 8 A). These results 
suggest that initial concentrations of siRNA were adequate to knockdown further 
HGPRT mRNA translation. Additionally, tests were performed in which transfection time 
was reduced from 48 to 24 hours to ensure that proliferation was being measured inside 
the previously established 120 hour window of HGPRT knockdown. Again, results were 
consistent with the original findings. AS1411 treated cells demonstrated decreased 
proliferation when compared to CRO or water treated cells. Transfections did not 
significantly alter levels of relative proliferation in either the CRO or water groups. These 
results indicate that data from initial time points were accurately reflected cellular 
proliferation from treatment and knockdown.  
Although consistent, this transfection data does not fully answer our previous 
question regarding siRNA knockdown of HGPRT. Was there no effect with AS1411 
treatment because the compound works by a non-HGPRT dependent mechanism, or 
because a residual population of HGPRT exists to preserve anti-proliferative activity? 
To answer this, we decided to test our siRNA HGPRT knockdown against GBPC anti-
proliferative activity. As mentioned previously, GBPCs have antagonistic effects on 
cellular growth, and these effects are known to be dependent on HGPRT activity [14 & 
15]. If AS1411 and GBPC activity works by an analogous mechanism due to similar 
chemical composition and exhibited anti-proliferative effects in cancer cell lines, this 
would mean that HGPRT siRNA transfections would affect the anti-proliferative effects 
of both compounds in a similar manner. If HGPRT knockdowns are unable to cause a 
change in GBPC activity, it would imply that siRNAs were unable to effectively reduce 
HGPRT activity and imply that residual pools of HGPRT are preserving AS1411 and 
GBPC function. Conversely, if the GBPCs do demonstrate decreases in activity in cells 
with decreased levels of HGPRT, it would imply that HGPRT siRNAs are able to 
efficiently knockdown HGPRT activity and that AS1411 works by a non-HGPRT 
mechanism.  
To test this hypothesis, the anti-proliferative effects of GBPCs in our cell lines 
needed to be established. A549 and MDA-MB-231 cells were treated with 
concentrations of Guo ranging from 25 – 400 µM. These concentrations were chosen in 
hopes of developing a dose-dependent response curve and to mimic concentrations of 
AS1411 used previously. AS1411 contains approximately 20 guanine bases, meaning 
that a 10 µM treatment of AS1411 would be equivalent to a 200 µM treatment of Guo. 
A549 and MDA-MB-231 cells both exhibited a response to high concentrations of Guo, 
but results were not as drastic as that seen in AS1411 treatments. Additionally, the cells 
demonstrated differing levels of response to the treatment, A549 cells treated with 400 
µM of Guo decreased in proliferation by approximately 40% when compared to the 
vehicle, whereas the decrease in MDA-MB-231 cells was closer to 20% (Figure 9). 
Treatments of 200 µM Guo did not decrease proliferation in either cell line to that which 
was seen in 10 µM treatments of AS1411 (Figure 5).  
With the reactivity of each cell line to GBPCs established, the activity of the Guo 
was then tested after transfection with HGPRT siRNAs with the same time points and 
protocols as previous AS1411 studies. Treatments of Guo in non-transfected cells 
followed previous patterns. A549 cells demonstrated a dose dependent response to 
Guo treatment, but MDA-MB-231 cells did not exhibit a strong dose dependent 
response. Furthermore, treatment with AS1411 caused greater decreases in 
proliferation than Guo, which is consistent with previous dose-response curves in 
AS1411 (Figure 5) and Guo (Figure 9). Unfortunately, results in MDA-MB-231 cells 
demonstrated decreases in proliferation in both negative control siRNA and HGPRT 
siRNA transfections suggesting a toxic side-effect of lipofectamine in MDA-MB-231 cells 
at that concentration. Of the eight Guo treatment groups between the two cells types, 
seven did not show significant differences between non-transfected, negative control 
siRNA transfections, and HGPRT siRNA transfections. One group displayed a 
statistically significant difference in proliferation among the transfection types, A549, 
200 µM Guo. In the majority of groups, HGPRT knockdown was unable to significantly 
alter Guo anti-proliferative activity. Therefore, these experiments have not determined 
whether or not the activity of AS1411 is the same as GBPCs. 
Expression knockdown via transfected siRNAs operates by engineering siRNAs 
with complimentary sequences to the mRNA of interest and delivering them into the cell 
via cationic liposomes [25]. Once inside the cell, the siRNAs integrate into the 
multiprotein RNAi induced silencing complex (RISC), which can target and degrade the 
desired mRNAs [26]. Although this process will knockdown the expression of a 
particular protein by a considerable amount, it will not target the preexisting proteins 
within the cell.  For proteins with short half-lives, this is not problematic for the 
experimental procedure; however, some proteins can have half-lives of over 100 hours 
[27]. Additionally, the proteins of cells in stressed environments where cellular division 
has been slowed or stopped can actually increase their half-lives [28]. HGPRT has a 
half-life of over 48 hours [29], which may be extended during periods of stress caused 
by treatments of AS1411 or Guo. Previous results demonstrate an incomplete ability to 
prevent HGPRT activity, which may be due in part to residual HGPRT inside the cell 
that is not silenced by siRNA transfection. 
In order to test the activity of these compounds in a HGPRT deficient 
environment, A549 cells were incubated in TG in order to select for HGPRT mutant 
cells. As mentioned previously, TG is toxic to cells with functioning HGPRT. HGPRT 
can transfer a phosphoribosyl group onto TG, allowing it to be incorporated into the 
DNA and cause strand breakages [20 & 21]. The employed protocol was based on 
previous work [22] that demonstrates how cells can be selected for HGPRT mutations 
for mutagenesis studies. After establishing A549 cell lines that could consistently grow 
in 15 µM TG, their proliferation in GBPCs and AS1411 were measured against wild type 
A549 cells. A statistically significant increase in proliferation was seen across multiple 
Guo treatments as well as in AS1411 treatments for cells incubated in 6-thioguanine 
over wild type counterparts. Although the mutant cells were not examined by a genomic 
assay, their ability to grow and proliferate while being incubated in TG suggests that the 
cells did not have a functioning copy of HGPRT. Coupled with the attenuated responses 
of HGPRT mutants to GBPC/AS1411 treatment, this suggests that HGPRT activity is 
vital for the activity of GBPCs and AS1411. Furthermore, the anti-proliferative activity of 
both AS1411 and GBPCs may likely operate by a similar, HGPRT dependent 
mechanism. While the results are promising, these experiments have a number of 
limitations. A lack of genomic testing of the TG treated cells to confirm mutations in the 
HPRT1 gene means that their TG resistance may not have come from a non HGPRT-
related mechanism. Although the vehicle control treatments in TG treated cells and 
wildtype cells did not demonstrate significant difference in proliferation, this result could 
have been skewed by the large error bar seen in the vehicle treated wildtype cells. 
Additionally, the experiment lacked a CRO control to ensure that differences in 
proliferation can be attributed to AS1411 and Guo anti-proliferative effects and not 
simply to physiological differences in the two cell lines due to TG related stress. 
Replication of the experiment with these additional controls would be necessary to 
confirm previous results.  
Future Directions 
 Although these results suggest a similar mechanism for AS1411 and GBPCs, 
more work is necessary to confirm this hypothesis. Replication of these experiments in 
additional cell lines that are more responsive to Guo treatment would help to strengthen 
this results. Additionally, genomic testing of TG-incubated A549 cells would be crucial to 
confirm mutations in the HPRT1 gene compromised the function of HGPRT. Moreover, 
a CRISPR/Cas9 system could be used to create an HGPRT deficient cell line 
analogous to HGPRT mutants to further confirm that previous results were due to the 
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